Cargando…
Treatment Options for Pancreatic Neuroendocrine Tumors
The management of pancreatic neuroendocrine tumors (PanNETs) involves classification into non-functional or functional PanNET, and as localized or metastatic PanNET. In addition, while most PanNETs are sporadic, these endocrine neoplasms can also be manifestations of genetic syndromes. All these fac...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6628351/ https://www.ncbi.nlm.nih.gov/pubmed/31207914 http://dx.doi.org/10.3390/cancers11060828 |
_version_ | 1783434939650277376 |
---|---|
author | Akirov, Amit Larouche, Vincent Alshehri, Sameerah Asa, Sylvia L. Ezzat, Shereen |
author_facet | Akirov, Amit Larouche, Vincent Alshehri, Sameerah Asa, Sylvia L. Ezzat, Shereen |
author_sort | Akirov, Amit |
collection | PubMed |
description | The management of pancreatic neuroendocrine tumors (PanNETs) involves classification into non-functional or functional PanNET, and as localized or metastatic PanNET. In addition, while most PanNETs are sporadic, these endocrine neoplasms can also be manifestations of genetic syndromes. All these factors may assist in forming a risk stratification system permitting a tailored management approach. Most PanNETs are classified as non-functional because they are not associated with clinical sequelae of hormone excess. They are characterized by non-specific symptoms, such as abdominal pain or weight loss, resulting from mass effect related to the pancreatic tumor or secondary to distant metastases. Accurate staging of the disease is essential for determining the appropriate approach to therapy. As cure is only potentially possible with surgical resection of the tumor, it is recommended to remove all localized and limited metastatic disease. However, many patients present with metastatic and/or advanced local disease. In such instances, the goal of therapy is to control tumor growth and/or decrease tumor burden, lengthen survival, and palliate local symptoms and those of hormone excess. This typically requires a multimodal approach, including surgery, liver-directed treatment, and systemic medical therapy. |
format | Online Article Text |
id | pubmed-6628351 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-66283512019-07-23 Treatment Options for Pancreatic Neuroendocrine Tumors Akirov, Amit Larouche, Vincent Alshehri, Sameerah Asa, Sylvia L. Ezzat, Shereen Cancers (Basel) Review The management of pancreatic neuroendocrine tumors (PanNETs) involves classification into non-functional or functional PanNET, and as localized or metastatic PanNET. In addition, while most PanNETs are sporadic, these endocrine neoplasms can also be manifestations of genetic syndromes. All these factors may assist in forming a risk stratification system permitting a tailored management approach. Most PanNETs are classified as non-functional because they are not associated with clinical sequelae of hormone excess. They are characterized by non-specific symptoms, such as abdominal pain or weight loss, resulting from mass effect related to the pancreatic tumor or secondary to distant metastases. Accurate staging of the disease is essential for determining the appropriate approach to therapy. As cure is only potentially possible with surgical resection of the tumor, it is recommended to remove all localized and limited metastatic disease. However, many patients present with metastatic and/or advanced local disease. In such instances, the goal of therapy is to control tumor growth and/or decrease tumor burden, lengthen survival, and palliate local symptoms and those of hormone excess. This typically requires a multimodal approach, including surgery, liver-directed treatment, and systemic medical therapy. MDPI 2019-06-14 /pmc/articles/PMC6628351/ /pubmed/31207914 http://dx.doi.org/10.3390/cancers11060828 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Akirov, Amit Larouche, Vincent Alshehri, Sameerah Asa, Sylvia L. Ezzat, Shereen Treatment Options for Pancreatic Neuroendocrine Tumors |
title | Treatment Options for Pancreatic Neuroendocrine Tumors |
title_full | Treatment Options for Pancreatic Neuroendocrine Tumors |
title_fullStr | Treatment Options for Pancreatic Neuroendocrine Tumors |
title_full_unstemmed | Treatment Options for Pancreatic Neuroendocrine Tumors |
title_short | Treatment Options for Pancreatic Neuroendocrine Tumors |
title_sort | treatment options for pancreatic neuroendocrine tumors |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6628351/ https://www.ncbi.nlm.nih.gov/pubmed/31207914 http://dx.doi.org/10.3390/cancers11060828 |
work_keys_str_mv | AT akirovamit treatmentoptionsforpancreaticneuroendocrinetumors AT larouchevincent treatmentoptionsforpancreaticneuroendocrinetumors AT alshehrisameerah treatmentoptionsforpancreaticneuroendocrinetumors AT asasylvial treatmentoptionsforpancreaticneuroendocrinetumors AT ezzatshereen treatmentoptionsforpancreaticneuroendocrinetumors |